Pipeline

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

By

The drugmaker is poised to cut 14 pipeline projects loose.

Allergan updates pipeline

Allergan updates pipeline

By

Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.

PhRMA uneasy about "right-to-try" laws

Colorado's version of the FDA's compassionate use rule does not sit well with lobbying group Pharmaceutical Research and Manufacturers of America.

Merck Q1 sales fall, but diabetes rises

Merck Q1 sales fall, but diabetes rises

By

Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

By

Roche also announced first-quarter sales shrank 1%.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Pfizer's Q4 fails to wow, but palbo' news may

Pfizer's Q4 fails to wow, but palbo' news may

By

The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Analyst: Don't underestimate AbbVie

Analyst: Don't underestimate AbbVie

By

Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.

Amgen PCSK9 drug passes safety test

New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.

Xeljanz line extension could lift drug's profile

Xeljanz line extension could lift drug's profile

By

An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.

Bayer: 5 new Phase III drugs expected in 2015

The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.

AstraZeneca reinforces oncology push

AstraZeneca reinforces oncology push

By

The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.

Analyst gives Merck tough love

By

Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.

Sleeper in Lilly oncology pipeline surprises Street

By

Phase III results of Eli Lilly lung cancer drug necitumumab took analysts by surprise on two levels: by helping it avoid the dustbin and in succeeding where Erbitux had failed.

Higher prices drive Lilly's second-quarter earnings

By

The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.

Roche diabetes pipeline shrinks to two

By

A Data and Safety Monitoring Board recommendation has wiped aleglitazar from the drug maker's slate of possible diabetes medications.

FDA pushes Merck's suvorexant aside

By

The regulator says Merck needs to focus on lower doses of the drug.

Which companies stand out post-ASCO?

Which companies stand out post-ASCO?

ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.

Victoza in its crosshairs, Lilly primes for marketing duel

By

Eli Lilly's GLP-1 drug is still in Phase III, but recently released data suggest it could be a formidable competitor to the already marketed GLP-1 drugs, including Novo's market-leading Victoza.

J&J expands pipeline in prostate cancer

By

The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug.

Novartis readying 2014 filing for lung cancer drug

Novartis readying 2014 filing for lung cancer drug

By

Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.

GSK gets 2 cancer pills approved, but a deeper question is left unanswered

GSK gets 2 cancer pills approved, but a deeper question is left unanswered

By

GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.

Business Briefs: Merck and Forest Labs

Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement.

J&J's Janssen looks to the margins with hep C agent

By

J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon.

Data show Gilead's sofosbuvir has 'clean' safety profile

By

Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.

Pfizer pipeline breast cancer drug gets fast tracked

By

FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.

Oncology lifts Roche's Q1, Lucentis finds new fans

Oncology lifts Roche's Q1, Lucentis finds new fans

By

Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.

More pink slips at AstraZeneca

By

Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.

Business briefs: Gilead, Shire, The Medicines Co., HHS

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.

Email Newsletters

MM&M inVISION